SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/18/20 Navidea Biopharmaceuticals, Inc. 10-K 12/31/19 97:10M RDG Filings/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.18M 2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 42K 3: EX-10.27 Material Contract HTML 92K 4: EX-10.28 Material Contract HTML 102K 5: EX-21.1 Subsidiaries List HTML 26K 6: EX-23.1 Consent of Experts or Counsel HTML 30K 7: EX-24.1 Power of Attorney HTML 33K 8: EX-31.1 Certification -- §302 - SOA'02 HTML 32K 9: EX-32.1 Certification -- §906 - SOA'02 HTML 28K 95: R1 Document And Entity Information HTML 67K 42: R2 Consolidated Balance Sheets HTML 133K 31: R3 Consolidated Balance Sheets (Parentheticals) HTML 48K 64: R4 Consolidated Statements of Operations HTML 109K 94: R5 Consolidated Statements of Comprehensive Loss HTML 38K 41: R6 Consolidated Statements of Stockholders' (Deficit) HTML 125K Equity 30: R7 Consolidated Statements of Stockholders' (Deficit) HTML 30K Equity (Parentheticals) 62: R8 Consolidated Statements of Cash Flows HTML 112K 97: R9 Note 1 - Organization and Summary of Significant HTML 127K Accounting Policies 55: R10 Note 2 - Liquidity HTML 43K 24: R11 Note 3 - Discontinued Operations HTML 33K 72: R12 Note 4 - Revenue From Contracts With Customers HTML 100K 82: R13 Note 5 - Fair Value HTML 54K 54: R14 Note 6 - Stock-based Compensation HTML 70K 23: R15 Note 7 - Loss Per Share HTML 33K 71: R16 Note 8 - Accounts and Other Receivables and HTML 41K Concentrations of Credit Risk 81: R17 Note 9 - Property and Equipment HTML 48K 53: R18 Note 10 - Investment in Macrophage Therapeutics, HTML 57K Inc. 25: R19 Note 11 - Accounts Payable, Accrued Liabilities HTML 40K and Other 57: R20 Note 12 - Notes Payable HTML 53K 89: R21 Note 13 - Leases HTML 69K 38: R22 Note 14 - Commitments and Contingencies HTML 73K 27: R23 Note 15 - Equity Instruments HTML 66K 56: R24 Note 16 - Income Taxes HTML 130K 88: R25 Note 17 - Segments HTML 144K 37: R26 Note 18 - Agreements HTML 43K 26: R27 Note 19 - Employee Benefit Plan HTML 32K 58: R28 Note 20 - Supplemental Disclosure for Statements HTML 34K of Cash Flows 87: R29 Note 21 - Subsequent Events HTML 34K 84: R30 Significant Accounting Policies (Policies) HTML 177K 74: R31 Note 1 - Organization and Summary of Significant HTML 44K Accounting Policies (Tables) 21: R32 Note 4 - Revenue From Contracts With Customers HTML 75K (Tables) 51: R33 Note 5 - Fair Value (Tables) HTML 46K 85: R34 Note 6 - Stock-based Compensation (Tables) HTML 64K 75: R35 Note 8 - Accounts and Other Receivables and HTML 38K Concentrations of Credit Risk (Tables) 22: R36 Note 9 - Property and Equipment (Tables) HTML 46K 52: R37 Note 11 - Accounts Payable, Accrued Liabilities HTML 36K and Other (Tables) 86: R38 Note 13 - Leases (Tables) HTML 63K 73: R39 Note 15 - Equity Instruments (Tables) HTML 44K 90: R40 Note 16 - Income Taxes (Tables) HTML 117K 60: R41 Note 17 - Segments (Tables) HTML 137K 34: R42 Note 1 - Organization and Summary of Significant HTML 111K Accounting Policies (Details Textual) 44: R43 Note 1 - Organization and Summary of Significant HTML 53K Accounting Policies - Assumptions Used to Calculate Fair Value of Stock Option Awards Granted (Details) 91: R44 Note 2 - Liquidity (Details Textual) HTML 80K 61: R45 Note 3 - Discontinued Operations (Details Textual) HTML 37K 36: R46 Note 4 - Revenue From Contracts With Customers HTML 66K (Details Textual) 45: R47 Note 4 - Revenue From Contracts With Customers - HTML 38K Change in Deferred Revenue and Accumulated Deficit (Details) 92: R48 Note 4 - Revenue From Contracts With Customers - HTML 43K Disaggregation of Revenue (Details) 59: R49 Note 4 - Revenue From Contracts With Customers - HTML 37K Changes in Contract Liabilities (Details) 67: R50 Note 5 - Fair Value (Details Textual) HTML 31K 78: R51 Note 5 - Fair Value - Financial Liabilities HTML 43K Measured at Fair Value on a Recurring Basis (Details) 50: R52 Note 6 - Stock-based Compensation (Details HTML 67K Textual) 20: R53 Note 6 - Stock-based Compensation - Summary of HTML 60K Stock Option Activity (Details) 66: R54 Note 6 - Stock-based Compensation - Summary of HTML 44K Unvested Restricted Stock (Details) 77: R55 Note 7 - Loss Per Share (Details Textual) HTML 32K 49: R56 Note 8 - Accounts and Other Receivables and HTML 38K Concentrations of Credit Risk (Details Textual) 19: R57 Note 8 - Accounts and Other Receivables and HTML 35K Concentrations of Credit Risk - Accounts and Other Receivables (Details) 68: R58 Note 9 - Property and Equipment (Details Textual) HTML 28K 76: R59 Note 9 - Property and Equipment - Summary of Major HTML 48K Classes of Property and Equipment (Details) 43: R60 Note 10 - Investment in Macrophage Therapeutics, HTML 105K Inc. (Details Textual) 32: R61 Note 11 - Accounts Payable, Accrued Liabilities HTML 34K and Other (Details Textual) 65: R62 Note 11 - Accounts Payable, Accrued Liabilities HTML 35K and Other - Accrued Liabilities and Other (Details) 96: R63 Note 12 - Notes Payable (Details Textual) HTML 147K 40: R64 Note 13 - Leases (Details Textual) HTML 61K 29: R65 Note 13 - Leases - Impact of the Adoption of ASU HTML 42K 2016-02 on Our Balance Sheet (Details) 63: R66 Note 13 - Leases - Amount, Timing and Uncertainty HTML 57K of Cash Flows Arising From Operating Leases (Details) 93: R67 Note 14 - Commitments and Contingencies (Details HTML 102K Textual) 39: R68 Note 15 - Equity Instruments (Details Textual) HTML 165K 33: R69 Note 15 - Equity Instruments - Outstanding HTML 45K Warrants (Details) 17: R70 Note 16 - Income Taxes (Details Textual) HTML 59K 46: R71 Note 16 - Income Taxes - Components of Deferred HTML 52K Tax Assets (Details) 79: R72 Note 16 - Income Taxes - Net Operating Loss and HTML 102K Credit Carryforwards (Details) 69: R73 Note 16 - Income Taxes - Reconciliations Between HTML 56K the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) 18: R74 Note 17 - Segments (Details Textual) HTML 38K 47: R75 Note 17 - Segments - Segment Information (Details) HTML 117K 80: R76 Note 18 - Agreements (Details Textual) HTML 71K 70: R77 Note 19 - Employee Benefit Plan (Details Textual) HTML 28K 16: R78 Note 20 - Supplemental Disclosure for Statements HTML 66K of Cash Flows (Details Textual) 48: R79 Note 21 - Subsequent Events (Details Textual) HTML 46K 35: XML IDEA XML File -- Filing Summary XML 178K 83: EXCEL IDEA Workbook of Financial Reports XLSX 93K 10: EX-101.INS XBRL Instance -- navb-20191231 XML 2.75M 12: EX-101.CAL XBRL Calculations -- navb-20191231_cal XML 141K 13: EX-101.DEF XBRL Definitions -- navb-20191231_def XML 2.14M 14: EX-101.LAB XBRL Labels -- navb-20191231_lab XML 1.49M 15: EX-101.PRE XBRL Presentations -- navb-20191231_pre XML 2.10M 11: EX-101.SCH XBRL Schema -- navb-20191231 XSD 274K 28: ZIP XBRL Zipped Folder -- 0001437749-20-005567-xbrl Zip 259K
Download this zipped .zip folder | |
Files: | navb-20191231.xml navb-20191231.xsd navb-20191231_cal.xml navb-20191231_def.xml navb-20191231_lab.xml navb-20191231_pre.xml |